An Open-label, Positive-controlled, Parallel-group Study to Determine the Effect of BRL 49653C, Rosiglitazone, on Body Fat Distribution When Administered for 26 Weeks to Patients with Type 2 Diabetes
Diabetes Mellitus, Type 2
Phase 3
An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
March 2015